PROFOUND MEDICAL CORP (PROF) Stock Overview
USA - NASDAQ:PROF - CA74319B5027 - Common Stock
PROF Key Statistics, Chart & Performance
The current stock price of PROF is 5.98 USD. In the past month the price increased by 46.21%. In the past year, price decreased by -22.84%.
PROF Latest News, Press Relases and Analysis
PROF Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.81 | 228.66B | ||
| ISRG | INTUITIVE SURGICAL INC | 54.13 | 156.20B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.55 | 140.69B | ||
| SYK | STRYKER CORP | 28.4 | 139.51B | ||
| MDT | MEDTRONIC PLC | 17.28 | 122.60B | ||
| BDX | BECTON DICKINSON AND CO | 13.08 | 53.50B | ||
| IDXX | IDEXX LABORATORIES INC | 52.73 | 50.67B | ||
| EW | EDWARDS LIFESCIENCES CORP | 28.39 | 42.83B | ||
| RMD | RESMED INC | 28.59 | 39.97B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.42 | 32.80B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.47 | 26.48B | ||
| DXCM | DEXCOM INC | 38.35 | 25.57B |
Related stock screener links
About PROF
Company Profile
Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-09-24. The company is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The company is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Company Info
PROFOUND MEDICAL CORP
2400 Skymark Ave Unit 6
Mississauga ONTARIO L4W 5K5 CA
CEO: Arun Menawat
Employees: 142
Phone: 16474761350
PROFOUND MEDICAL CORP / PROF FAQ
What is the stock price of PROFOUND MEDICAL CORP today?
The current stock price of PROF is 5.98 USD. The price increased by 1.87% in the last trading session.
What is the ticker symbol for PROFOUND MEDICAL CORP stock?
The exchange symbol of PROFOUND MEDICAL CORP is PROF and it is listed on the Nasdaq exchange.
On which exchange is PROF stock listed?
PROF stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PROFOUND MEDICAL CORP stock?
6 analysts have analysed PROF and the average price target is 11.09 USD. This implies a price increase of 85.49% is expected in the next year compared to the current price of 5.98. Check the PROFOUND MEDICAL CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PROFOUND MEDICAL CORP worth?
PROFOUND MEDICAL CORP (PROF) has a market capitalization of 180.12M USD. This makes PROF a Micro Cap stock.
How many employees does PROFOUND MEDICAL CORP have?
PROFOUND MEDICAL CORP (PROF) currently has 142 employees.
What are the support and resistance levels for PROFOUND MEDICAL CORP (PROF) stock?
PROFOUND MEDICAL CORP (PROF) has a support level at 5.55 and a resistance level at 5.99. Check the full technical report for a detailed analysis of PROF support and resistance levels.
Is PROFOUND MEDICAL CORP (PROF) expected to grow?
The Revenue of PROFOUND MEDICAL CORP (PROF) is expected to grow by 51.68% in the next year. Check the estimates tab for more information on the PROF EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PROFOUND MEDICAL CORP (PROF) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PROF, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PROF, evaluating the profitability, health, valuation and growth aspects
- PROFOUND MEDICAL CORP (PROF) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PROFOUND MEDICAL CORP (PROF) Sales and EPS estimates to see what analysts future expectations are.
- PROFOUND MEDICAL CORP (PROF) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PROFOUND MEDICAL CORP (PROF) Insider and Institutional Ownership to learn about the owners and their transactions.
- PROFOUND MEDICAL CORP (PROF) Stock Chart to make your own analysis
- PROFOUND MEDICAL CORP (PROF) Latest news and press-releases to stay up to date.
Does PROFOUND MEDICAL CORP (PROF) stock pay dividends?
PROF does not pay a dividend.
When does PROFOUND MEDICAL CORP (PROF) report earnings?
PROFOUND MEDICAL CORP (PROF) will report earnings on 2025-10-30, after the market close.
What is the Price/Earnings (PE) ratio of PROFOUND MEDICAL CORP (PROF)?
PROFOUND MEDICAL CORP (PROF) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.46).
What is the Short Interest ratio of PROFOUND MEDICAL CORP (PROF) stock?
The outstanding short interest for PROFOUND MEDICAL CORP (PROF) is 2.79% of its float. Check the ownership tab for more information on the PROF short interest.
PROF Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to PROF. When comparing the yearly performance of all stocks, PROF is a bad performer in the overall market: 77.96% of all stocks are doing better.
PROF Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PROF. While PROF seems to be doing ok healthwise, there are quite some concerns on its profitability.
PROF Financial Highlights
Over the last trailing twelve months PROF reported a non-GAAP Earnings per Share(EPS) of -1.46. The EPS decreased by -19.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.01% | ||
| ROE | -103.75% | ||
| Debt/Equity | 0.12 |
PROF Forecast & Estimates
6 analysts have analysed PROF and the average price target is 11.09 USD. This implies a price increase of 85.49% is expected in the next year compared to the current price of 5.98.
For the next year, analysts expect an EPS growth of -38.2% and a revenue growth 51.68% for PROF